Global X Genomics & Biotechnology ETF
GNOM
39 hedge funds and large institutions have $76.4M invested in Global X Genomics & Biotechnology ETF in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 15 increasing their positions, 2 reducing their positions, and 5 closing their positions.
650% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 2
260% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 5
50% more funds holding
Funds holding: 26 → 39 (+13)
28% more capital invested
Capital invested by funds: $59.9M → $76.4M (+$16.6M)
4.52% less ownership
Funds ownership: 13.76% → 9.23% (-4.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$19.8M |
| 2 |
MIG
McGuire Investment Group
Wakefield,
Rhode Island
|
+$6.59M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$5.39M |
| 4 |
T
TRUADVICE
Sarasota,
Florida
|
+$3.31M |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$1.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$17.8M |
| 2 |
Jane Street
New York
|
-$2.19M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$509K |
| 4 |
CFGS
Concourse Financial Group Securities
Birmingham,
Alabama
|
-$62.9K |
| 5 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$12K |
GNOM Hedge Fund Activity: Q1 2021 in Review
39 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Global X Genomics & Biotechnology ETF (GNOM) for Q1 2021, worth a combined $76.4M — up 28% from $59.9M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new GNOM positions and 5 closed out — a net gain of 13 holders — while 15 added to existing stakes and 2 trimmed.
The largest buyer was Mirae Asset Global Investments, adding an estimated $19.8M. The largest seller was Citigroup, exiting entirely with an estimated $17.8M sold.
- 39 institutional investors held Global X Genomics & Biotechnology ETF (GNOM) as of Q1 2021, up from 26 in Q4 2020.
- Funds reported $76.4M of Global X Genomics & Biotechnology ETF stock for Q1 2021, up 28% quarter-over-quarter.
- 18 funds opened new Global X Genomics & Biotechnology ETF positions in Q1 2021 and 5 closed out, a net change of +13 holders.
- The largest Global X Genomics & Biotechnology ETF buyer in Q1 2021 was Mirae Asset Global Investments, an estimated $19.8M added.
- The largest Global X Genomics & Biotechnology ETF seller in Q1 2021 was Citigroup, an estimated $17.8M sold.
Based on aggregated 13F filings for Q1 2021.